Identifying Patients for Self-Administration of Omalizumab.
Allergic asthma
Chronic spontaneous urticaria
Nasal polyps
Omalizumab
Self-administration
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
02
07
2022
accepted:
19
08
2022
pubmed:
30
9
2022
medline:
25
1
2023
entrez:
29
9
2022
Statut:
ppublish
Résumé
Omalizumab, a recombinant anti-immunoglobulin E (IgE) monoclonal antibody, is indicated for moderate to severe allergic asthma, chronic spontaneous urticaria, and nasal polyps, and is approved for self-administration. However, specific guidance on identifying candidates with characteristics suitable for this type of administration is lacking. To help address this issue, this article provides practical considerations for the health care provider treating patients with omalizumab. We encourage health care providers to consider self-administration of omalizumab as an option for all appropriate, but not all, patients, and we recommend an individualized approach when considering self-administration of omalizumab.
Identifiants
pubmed: 36173511
doi: 10.1007/s12325-022-02308-w
pii: 10.1007/s12325-022-02308-w
pmc: PMC9859916
doi:
Substances chimiques
Omalizumab
2P471X1Z11
Antibodies, Monoclonal, Humanized
0
Anti-Allergic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
19-24Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Xolair Prescribing Information. South San Francisco, California: Genentech, Inc. 2021.
Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32:425–40.
doi: 10.1007/s40259-018-0295-0
Thurman JE. Analysis of insulin pen devices for the treatment of diabetes mellitus. J Diabetes Sci Technol. 2008;2:482–3.
doi: 10.1177/193229680800200319
Sparrow MP. Adalimumab in ulcerative colitis-efficacy, safety and optimization in the era of treat-to target. Expert Opin Biol Ther. 2017;17:613–21.
doi: 10.1080/14712598.2017.1309390
Schiff M, Saunderson S, Mountian I, Hartley P. Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment. Rheumatol Ther. 2017;4:445–63.
doi: 10.1007/s40744-017-0080-4
Callis Duffin K, Bagel J, Bukhalo M, et al. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017;31:107–13.
doi: 10.1111/jdv.13768
Ito M, Kamata M, Uchida H, et al. Introduction of self-injection increases compliance with dupilumab administration in adult patients with atopic dermatitis: a single-center retrospective study. JAAD Int. 2020;1:91–2.
doi: 10.1016/j.jdin.2020.06.004
Platteau P, Laurent E, Albano C, et al. An open, randomized single-centre study to compare the efficacy and convenience of follitropin beta administered by a pen device with follitropin alpha administered by a conventional syringe in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod. 2003;18:1200–4.
doi: 10.1093/humrep/deg234
Rohrer TR, Horikawa R, Kappelgaard AM. Growth hormone delivery devices: current features and potential for enhanced treatment adherence. Expert Opin Drug Deliv. 2017;14:1253–64.
doi: 10.1080/17425247.2017.1243526
Lombardi C, Bagnasco D, Passalacqua G. Biological agents for severe asthma: the evolution of the at-home self-injection approach. Curr Opin Allergy Clin Immunol. 2020;20:421–7.
doi: 10.1097/ACI.0000000000000656
Menzella F, Ferrari E, Ferrucci SM, et al. Self-administration of omalizumab: why not? A literature review and expert opinion. Expert Opin Biol Ther. 2021;21:499–507.
doi: 10.1080/14712598.2021.1882990
Timmermann H, Mailänder C. Home self-administration of biologics: a German survey among omalizumab-treated oatients with severe asthma and their treating physicians. Pneumologie. 2020;74:103–11.
doi: 10.1055/a-1069-0900
Náfrádi L, Nakamoto K, Schulz PJ. Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. PLoS ONE. 2017;12: e0186458.
doi: 10.1371/journal.pone.0186458
Tonna A, Anthony G, Tonna I, et al. Home self-administration of intravenous antibiotics as part of an outpatient parenteral antibiotic therapy service: a qualitative study of the perspectives of patients who do not self-administer. BMJ Open. 2019;9: e027475.
doi: 10.1136/bmjopen-2018-027475
Hiley J, Homer D, Clifford C. Patient self-injection of methotrexate for inflammatory arthritis: a study evaluating the introduction of a new type of syringe and exploring patients’ sense of empowerment. Musculoskelet Care. 2008;6:15–30.
doi: 10.1002/msc.114
Munsell M, Frean M, Menzin J, Phillips AL. An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug. Patient Prefer Adher. 2017;11:55–62.
doi: 10.2147/PPA.S118107
Denman S, Ford K, Toolan J, et al. Home self-administration of omalizumab for chronic spontaneous urticaria. Br J Dermatol. 2016;175:1405–7.
doi: 10.1111/bjd.15074
Ghazanfar M, Holm J, Thomsen SF. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study. J Eur Acad Dermatol Venereol. 2018;32:1761–7.
doi: 10.1111/jdv.15045
Greenhawt M, Shaker M. Keeping risk in context while rethinking the setting of asthma biologics in patient-centered care. Ann Allergy Asthma Immunol. 2020;125:124–5.
doi: 10.1016/j.anai.2020.05.029
Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab. J Allergy Clin Immunol. 2020;8:565–72.
Bukstein DA, Guerra DG Jr, Huwe T, Davis RA. A review of shared decision-making: a call to arms for health care professionals. Ann Allergy Asthma Immunol. 2020;125:273–9.
doi: 10.1016/j.anai.2020.06.030